Companies

Dr Reddy’s Labs launches Capecitabine tablets in US market

Hyderabad | Updated on February 17, 2021 Published on February 17, 2021

The tablets are available in 150/500 mg strengths

Dr Reddy’s Laboratories has announced the launch of Capecitabine Tablets, USP, a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the US Food and Drug Administration (USFDA).

The Xeloda brand and generic had US sales of approximately $90 million MAT for the most recent twelve months ending October 2020, according to IQVIA Health.

Dr Reddy’s to launch 25 products in US this fiscal

Dr Reddy’s Capecitabine Tablets are available in 150 mg and 500 mg strengths in bottle count sizes of 60 and 120, respectively.

Patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy should have their anticoagulant response monitored frequently in order to adjust the anticoagulant dose accordingly, it said in a statement.

Dr Reddy’s ADRs list on NSE IFSC

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 17, 2021
USA
Dr Reddys Laboratories Ltd
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.